~ 股东年度/特别会议将于 2026 年 1 月 30 日举行 ~
宾夕法尼亚州韦克斯福德，2026 年 1 月 6 日（环球新闻通讯）-- Coeptis Therapeutics Holdings, Inc.（纳斯达克代码：COEP）（“Coeptis” 或 “公司”），一家下一代技术和生物制药公司，今天宣布其在美国证券交易委员会（“SEC”）注册的 S-4 表格（文件编号：333-288329）（经修订的 “注册声明”）已被宣布生效，该注册声明与之前宣布的与 Z Squared Inc.（“ZSQ”）的合并交易（“交易”）相关。公司将开始向截至 2026 年 1 月 2 日（“记录日期”）营业结束时的股东邮寄与股东年度/特别会议（“股东会议”）相关的最终代理声明/招股说明书，会议定于 2026 年 1 月 30 日举行。股东会议的通知将于 2026 年 1 月 7 日左右邮寄给截至记录日期的股东。
虽然合并公司已提交申请在纳斯达克证券市场上市，但尚未获得批准，且无法保证该上市申请将获得批准，或合并公司将符合适用的上市标准。如果合并公司无法在国家证券交易所获得上市，其证券将在交易后继续在场外市场交易。
关于 Coeptis。
COEPTIS, Inc.及其子公司 Coeptis Pharmaceuticals, Inc.、GEAR Therapeutics, Inc.、SNAP Biosciences, Inc.和 Coeptis Technologies, Inc.（统称 “Coeptis”）是一家生物制药和技术公司。生物制药部门专注于开发用于癌症、自身免疫和传染病的创新细胞治疗平台。Coeptis 旨在通过其前沿的研究和开发工作推进治疗范式并改善患者结果。
公司的治疗组合以从 Deverra Therapeutics 获得的资产为基础，包括一种异体细胞免疫疗法平台和 DVX201，一种临床阶段的未修饰自然杀伤细胞治疗技术。COEPTIS 还正在开发一种从匹兹堡大学获得的通用多抗原 CAR 技术（SNAP-CAR），以及与 VyGen-Bio 和卡罗林斯卡学院的杰出医学研究人员合作的 GEAR 细胞治疗和伴随诊断平台。
基于其核心竞争力，COEPTIS 最近成立了一个技术部门，专注于通过先进技术增强运营能力。该部门拥有从 NexGenAI Solutions Group 获得的人工智能驱动的营销软件和机器人流程自动化工具，旨在优化业务流程并提高整体效率。
COEPTIS 总部位于宾夕法尼亚州韦克斯福德，致力于在 FDA 设定的监管框架内推进其使命，确保所有活动符合最高的合规和患者护理标准。有关 COEPTIS 的更多信息，请访问 https://coeptistx.com。
关于 Z Squared： Z Squared 致力于建立一个可持续和高效的加密货币挖矿运营，并在可信的中型矿工中占据一席之地，拥有 9000 台专注于狗狗币（DOGE）、莱特币（LTC）的 ASIC 矿机，分别对应其 200 亿美元和 60 亿美元的市值。我们的目标是负责任地增长，利用先进技术和战略运营，确立自己在美国矿业行业中的重要地位。
征求参与者 Coeptis、Z Squared Inc.及其各自的董事、高级管理人员、其他管理成员和员工可能被视为参与征求 Coeptis 和 Z Squared 股东对拟议交易的代理。投资者和证券持有人可以在向 SEC 提交的拟议交易的代理声明/招股说明书中获得有关 Coeptis 和 Z Squared 的董事和高级管理人员的姓名和在交易中的利益的更详细信息，包括注册声明。
无报价或征求 本新闻稿不构成对任何证券或拟议交易的代理、同意或授权的征求。本新闻稿也不构成出售或征求购买任何证券的报价，亦不应在任何州或司法管辖区进行证券的销售，除非在该等司法管辖区的证券法下注册或资格之前，此类报价、征求或销售是非法的。除非通过符合 1933 年证券法（经修订）要求的招股说明书，否则不得进行证券的发行。
关于前瞻性声明的警示说明 本新闻稿包含根据 1995 年《私人证券诉讼改革法》定义的前瞻性声明。前瞻性声明包括有关计划、目标、策略、未来事件或业绩的声明，以及潜在假设和其他非历史事实的声明。当我们使用诸如 “可能”、“将”、“打算”、“应该”、“相信”、“期望”、“预期”、“项目”、“估计” 或类似表达时，这些表达并不单纯与历史事项相关，而是在做出前瞻性声明。前瞻性声明并不保证未来的业绩，并涉及可能导致实际结果与我们在前瞻性声明中讨论的预期显著不同的风险和不确定性。这些声明受到重大不确定性和风险的影响，包括但不限于 Coeptis 向证券交易委员会提交的报告中包含的风险。因此，投资者被警告不要对本新闻稿中的任何前瞻性声明过度依赖。其他因素在 Coeptis 向美国证券交易委员会的备案中进行了讨论，包括注册声明，相关文件可在 www.sec.gov 上查阅。除非法律、法规或规则要求，Coeptis 和 Z Squared 均不承担公开修订这些前瞻性声明以反映本声明日期后发生的事件或情况的义务。
联系方式
IR@coeptistx.com
<img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1ERXpOQ00zTXpRME56TTFJekl5TURZek16Zz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1ERXpOQ00zTXpRME56TTFJekl5TURZek16Zz0"/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGQ4NjFlNzYtNTZiNy00YzM2LTk5MDktZjUzYzk4YWUwMDk3LTEyMTc4OTEtMjAyNi0wMS0wNi1lbg==/tiny/Coeptis-Therapeutics.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGQ4NjFlNzYtNTZiNy00YzM2LTk5MDktZjUzYzk4YWUwMDk3LTEyMTc4OTEtMjAyNi0wMS0wNi1lbg==/tiny/Coeptis-Therapeutics.png"/>

COEP

Coeptis Therapeutics 宣布，其与 Z Squared 合并的 S-4 注册声明已获得美国证券交易委员会（SEC）的有效批准。正式的代理声明将在 2026 年 1 月 30 日的年度/特别会议之前邮寄给股东。合并后的公司已申请纳斯达克上市，但批准尚待确认。如果未获批准，股票将在 OTC Markets 交易。Coeptis 专注于创新生物制药，而 Z Squared 则从事加密货币挖矿。此公告不构成对证券的招揽或出售要约

~ Annual/Special Meeting of Shareholders to be Held on January 30, 2026 ~
<div class="lb-trans">~ 股东年度/特别会议将于 2026 年 1 月 30 日举行 ~
</div>WEXFORD, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, , announced today that its registration statement on Form S-4 (File No. 333-288329) (as amended, the “Registration Statement”), relating to the previously announced merger transaction (the “Transaction”) with Z Squared Inc. (“ZSQ”), has been declared effective by the U.S. Securities and Exchange Commission (“SEC”) and that it will commence mailing the definitive proxy statement/prospectus relating to the Annual/Special Meeting (the “Stockholder Meeting”) of the Company’s stockholders to be held on January 30, 2026, in connection with the Transaction. The proxy statement/prospectus is being mailed to the Company’s stockholders of record as of the close of business on January 2, 2026 (the “Record Date”). Notice of the Stockholder Meeting will be mailed on or about January 7, 2026 to stockholders of record as of the Record Date.
<div class="lb-trans">宾夕法尼亚州韦克斯福德，2026 年 1 月 6 日（环球新闻通讯）-- Coeptis Therapeutics Holdings, Inc.（纳斯达克代码：COEP）（“Coeptis” 或 “公司”），一家下一代技术和生物制药公司，今天宣布其在美国证券交易委员会（“SEC”）注册的 S-4 表格（文件编号：333-288329）（经修订的 “注册声明”）已被宣布生效，该注册声明与之前宣布的与 Z Squared Inc.（“ZSQ”）的合并交易（“交易”）相关。公司将开始向截至 2026 年 1 月 2 日（“记录日期”）营业结束时的股东邮寄与股东年度/特别会议（“股东会议”）相关的最终代理声明/招股说明书，会议定于 2026 年 1 月 30 日举行。股东会议的通知将于 2026 年 1 月 7 日左右邮寄给截至记录日期的股东。
</div>While the combined company has submitted an application to list the combined company’s common stock on The Nasdaq Stock Market LLC, approval has not yet been obtained and there can be no assurance that such listing application will be approved or that the combined company will meet the applicable listing standards. If the combined company is unable to obtain listing on a national securities exchange, the combined company’s securities will continue to trade on the OTC Markets following the Transaction.
<div class="lb-trans">虽然合并公司已提交申请在纳斯达克证券市场上市，但尚未获得批准，且无法保证该上市申请将获得批准，或合并公司将符合适用的上市标准。如果合并公司无法在国家证券交易所获得上市，其证券将在交易后继续在场外市场交易。
</div>About Coeptis.
<div class="lb-trans">关于 Coeptis。
</div>COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies, Inc (collectively &#34;Coeptis&#34;), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
<div class="lb-trans">COEPTIS, Inc.及其子公司 Coeptis Pharmaceuticals, Inc.、GEAR Therapeutics, Inc.、SNAP Biosciences, Inc.和 Coeptis Technologies, Inc.（统称 “Coeptis”）是一家生物制药和技术公司。生物制药部门专注于开发用于癌症、自身免疫和传染病的创新细胞治疗平台。Coeptis 旨在通过其前沿的研究和开发工作推进治疗范式并改善患者结果。
</div>The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
<div class="lb-trans">公司的治疗组合以从 Deverra Therapeutics 获得的资产为基础，包括一种异体细胞免疫疗法平台和 DVX201，一种临床阶段的未修饰自然杀伤细胞治疗技术。COEPTIS 还正在开发一种从匹兹堡大学获得的通用多抗原 CAR 技术（SNAP-CAR），以及与 VyGen-Bio 和卡罗林斯卡学院的杰出医学研究人员合作的 GEAR 细胞治疗和伴随诊断平台。
</div>Building on its core competencies, COEPTIS has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
<div class="lb-trans">基于其核心竞争力，COEPTIS 最近成立了一个技术部门，专注于通过先进技术增强运营能力。该部门拥有从 NexGenAI Solutions Group 获得的人工智能驱动的营销软件和机器人流程自动化工具，旨在优化业务流程并提高整体效率。
</div>Headquartered in Wexford, PA, COEPTIS is dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest standards of compliance and patient care. For more information on COEPTIS, visit https://coeptistx.com.
<div class="lb-trans">COEPTIS 总部位于宾夕法尼亚州韦克斯福德，致力于在 FDA 设定的监管框架内推进其使命，确保所有活动符合最高的合规和患者护理标准。有关 COEPTIS 的更多信息，请访问 https://coeptistx.com。
</div>About Z Squared: Z Squared is dedicated to building a sustainable and efficient cryptocurrency mining operation and is positioned among credible mid-cap miners with 9,000 actively generating ASIC miners focused on Dogecoin (DOGE), Litecoin (LTC) and addressing its $20B and $6B market caps, respectively. Our aim is to grow responsibly, leveraging advanced technology and strategic operations to establish ourselves as a significant player in the U.S. mining industry.
<div class="lb-trans">关于 Z Squared： Z Squared 致力于建立一个可持续和高效的加密货币挖矿运营，并在可信的中型矿工中占据一席之地，拥有 9000 台专注于狗狗币（DOGE）、莱特币（LTC）的 ASIC 矿机，分别对应其 200 亿美元和 60 亿美元的市值。我们的目标是负责任地增长，利用先进技术和战略运营，确立自己在美国矿业行业中的重要地位。
</div>Participants in the Solicitation Coeptis, Z Squared Inc. and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Coeptis’ and Z Squared’s stockholders with respect to the proposed Transaction. Investors and securityholders may obtain more detailed information regarding the names and interests in the Transaction of the directors and officers of each of Coeptis and Z Squared in the proxy statement/prospectus for the proposed Transaction as field with the SEC, including the Registration Statement.
<div class="lb-trans">征求参与者 Coeptis、Z Squared Inc.及其各自的董事、高级管理人员、其他管理成员和员工可能被视为参与征求 Coeptis 和 Z Squared 股东对拟议交易的代理。投资者和证券持有人可以在向 SEC 提交的拟议交易的代理声明/招股说明书中获得有关 Coeptis 和 Z Squared 的董事和高级管理人员的姓名和在交易中的利益的更详细信息，包括注册声明。
</div>No Offer or Solicitation This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed Transaction. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.
<div class="lb-trans">无报价或征求 本新闻稿不构成对任何证券或拟议交易的代理、同意或授权的征求。本新闻稿也不构成出售或征求购买任何证券的报价，亦不应在任何州或司法管辖区进行证券的销售，除非在该等司法管辖区的证券法下注册或资格之前，此类报价、征求或销售是非法的。除非通过符合 1933 年证券法（经修订）要求的招股说明书，否则不得进行证券的发行。
</div>Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When we use words such as &#34;may,&#34; &#34;will,&#34; &#34;intend,&#34; &#34;should,&#34; &#34;believe,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;project,&#34; &#34;estimate&#34; or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantee of future performance and involve risks and uncertainties that may cause the actual results to differ materially from our expectations discussed in the forward-looking statements. These statements are subject to significant uncertainties and risks including, but not limited, to those risks contained in reports filed by Coeptis with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Coeptis’ filings with the U.S. Securities and Exchange Commission, including the Registration Statement, which are available for review at www.sec.gov. Neither Coeptis nor Z Squared undertake any obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations or rules.
<div class="lb-trans">关于前瞻性声明的警示说明 本新闻稿包含根据 1995 年《私人证券诉讼改革法》定义的前瞻性声明。前瞻性声明包括有关计划、目标、策略、未来事件或业绩的声明，以及潜在假设和其他非历史事实的声明。当我们使用诸如 “可能”、“将”、“打算”、“应该”、“相信”、“期望”、“预期”、“项目”、“估计” 或类似表达时，这些表达并不单纯与历史事项相关，而是在做出前瞻性声明。前瞻性声明并不保证未来的业绩，并涉及可能导致实际结果与我们在前瞻性声明中讨论的预期显著不同的风险和不确定性。这些声明受到重大不确定性和风险的影响，包括但不限于 Coeptis 向证券交易委员会提交的报告中包含的风险。因此，投资者被警告不要对本新闻稿中的任何前瞻性声明过度依赖。其他因素在 Coeptis 向美国证券交易委员会的备案中进行了讨论，包括注册声明，相关文件可在 www.sec.gov 上查阅。除非法律、法规或规则要求，Coeptis 和 Z Squared 均不承担公开修订这些前瞻性声明以反映本声明日期后发生的事件或情况的义务。
</div>Contacts
<div class="lb-trans">联系方式
</div>IR@coeptistx.com
<div class="lb-trans">IR@coeptistx.com
</div><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1ERXpOQ00zTXpRME56TTFJekl5TURZek16Zz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyMDEzNCM3MzQ0NzM1IzIyMDYzMzg="/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGQ4NjFlNzYtNTZiNy00YzM2LTk5MDktZjUzYzk4YWUwMDk3LTEyMTc4OTEtMjAyNi0wMS0wNi1lbg==/tiny/Coeptis-Therapeutics.png" alt="" original-src="https://ml.globenewswire.com/media/MGQ4NjFlNzYtNTZiNy00YzM2LTk5MDktZjUzYzk4YWUwMDk3LTEyMTc4OTEtMjAyNi0wMS0wNi1lbg==/tiny/Coeptis-Therapeutics.png"/>

Coeptis Therapeutics 的 S-4 文件已被 SEC 宣布生效，代理邮件已开始发送，预计将与 Z Squared 进行合并交易 | COEP 股票新闻